Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Especially, there is no therapeutic strategy targeting the dysregulated host response. CXCR4-expressing neutrophils seem to be involved in the rupture of host resistance. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors.
Influenza is still responsible for more than 650,000 deaths per year worldwide and no major improvements in patients' care has been made despite 50 years of research. Most of severe influenza patients suffer from acute lung injury due to a dysregulated immune response. Neutrophils are involved in both host resistance and disease tolerance. Thanks to advances in technologies, the vast variety in neutrophils subpopulations has been revealed. In particular, the subpopulation of CXCR4-expressing neutrophils has been suggested to be involved in the rupture of disease tolerance in lung infections. Nevertheless, these data are from murine models and remain to be confirmed in humans. Moreover, the underlying mechanisms remain unknown as well as the place of primum movens, i.e. vascular or alveolar compartment. The aim of this study is thus to compare the percentage of blood CXCR4-expressing neutrophils between influenza survivors and non-survivors. Percentage of BAL CXCR4-expressing neutrophils will also be compared. To this aim, blood sampling and BAL within the 24 hours and at day 3 after admission to ICU, neutrophils isolation, immunostaining and flow cytometry acquisition will be performed within the 24 hours and at day 3 after admission to ICU. Mortality rate will be collected at Day 28 and Day 90.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Influenza-related ARDS group | Person with influenza virus infection proven by a positive polymerase chain reaction test for the influenza ARDS group. Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample. |
| |
| Bacterial-related ARDS group | A person with a proven bacterial infection (105 colony-forming units/mL for tracheal aspirates and more than 104 colony-forming units/mL for BAL). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample. |
| |
| Extra-pulmonary (digestive inflammation) ARDS group | Person presenting with acute pancreatitis according to the 2013 international recommendations (typical pain, lipasemia above 3 times normal and/or abnormality on imaging). Or Person presenting with acute bacterial peritonitis based on a clinical diagnosis and bacteria isolated on peritoneal samples (RFE SFAR 2018). Additional tubes taken when blood is drawn during treatment, and bronchoalveolar fluid sample. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Additional tubes and LBA | Other | 4 Additional tubes taken when blood is drawn during treatment : EDTA tubes and 2 citrate tubes and bronchoalveolar fluid sample (LBA) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Biological | Percentage of blood CXCR4-expressing neutrophils within the 24 hours following admission to ICU for invasive mechanical ventilation. | Day 1 after inclusion |
| Clinical | Mortality | Day 28 after inclusion |
Not provided
Not provided
Inclusion Criteria:
Patient aged 18 yo or above.
Acute respiratory distress syndrome as defined by the Berlin classification.
Invasive mechanical ventilation for less than 24 hours.
Cause of ARDS:
Health insurance.
Written informed consent from legal relative or representative.
Exclusion Criteria:
Neutropenia (< 500/mm3)
Neutrophils qualitative defect.
Patient included in an interventional research assessing an immunomodulatory or antiviral drug.
Acquired ImmunoDeficiency Syndrome.
Contraindication to BAL:
Legal restriction: prisoners, pregnancy, legal protection.
Not provided
Not provided
Not provided
The population of interest will be patients with acute respiratory distress syndrome according to the Berlin criteria.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Renaud PREVEL, Dr | Contact | 5 57 87 26 26 | +33 | renaud.prevel@u-bordeaux.fr |
| Name | Affiliation | Role |
|---|---|---|
| Edouard LHOMME, Dr | Unité de Soutien Méthodologique à la Recherche clinique et épidémiologique du CHU de Bordeaux | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hopital Pellegrin | Recruiting | Bordeaux | 33000 | France |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C428703 | LRBA protein, human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Hopital Haut-Lévêque | Not yet recruiting | Pessac | 33604 | France |
|
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D008171 | Lung Diseases |
| D012120 | Respiration Disorders |